Alpha 2.0
Login Register
» Authors » JonDavid Sparks

JonDavid Sparks

Explore the profile of JonDavid Sparks including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 1158
Followers 0
Related Specialties
Psychiatry
Neurology
Pharmacology
Top 10 Co-Authors
Matthew Rizzo
John R Sims
Paul Ardayfio
Hong Wang
Mark Bangs
Alette M Wessels
Cynthia D Evans
Scott Andersen
Celine Goldberger
Sanjay Dube
Published In
JAMA Neurol
Ann Neurol
J Psychosom Res
Proc Int Driv Symp Hum Factors Driv Assess Train Veh Des
Drugs Context
Affiliations
Soon will be listed here.
Recent Articles
1.
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials
Zimmer J, Ardayfio P, Wang H, Khanna R, Evans C, Lu M, et al.
JAMA Neurol . 2025 Mar; PMID: 40063015
Importance: Amyloid-related imaging abnormalities (ARIA) are the major adverse event associated with amyloid-targeting immunotherapy. Identifying clinical features and individual risk factors for ARIA could facilitate effective prediction and prevention strategies....
2.
ARIA Insights from the Donanemab Trials (P1-9.001)
Greenberg S, Battioui C, Lu M, Biffi A, Ardayfio P, Zimmer J, et al.
Neurology . 2025 Feb; 102(7_supplement_1):3339. PMID: 39977935
Objective: To characterize amyloid-related imaging abnormalities (ARIA) risk associated with donanemab, a novel amyloid-targeting therapy (ATT). Background: ARIA is an important safety concern associated with the class of ATTs. Identifying...
3.
An innovative phase 2 chronic pain master protocol design to assess novel mechanisms in multiple pain types
Knopp K, Downing A, Anthony L, Chaterjee S, Price K, Sparks J
Pain Rep . 2024 Oct; 9(6):e1203. PMID: 39430683
Introduction: The phase 2 chronic pain master protocol (CPMP) presented here provides a construct to accelerate the investigation of novel analgesics, broadly referred to here as mechanisms. Designed to address...
4.
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims J, Zimmer J, Evans C, Lu M, Ardayfio P, Sparks J, et al.
JAMA . 2023 Jul; 330(6):512-527. PMID: 37459141
Importance: There are limited efficacious treatments for Alzheimer disease. Objective: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. Design, Setting, And Participants:...
5.
APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials
Evans C, Sparks J, Andersen S, Brooks D, Hauck P, Mintun M, et al.
Alzheimers Dement . 2023 May; 19(12):5407-5417. PMID: 37204338
Introduction: Apolipoprotein E (APOE) ε4 may interact with response to amyloid-targeting therapies. Methods: Aggregate data from trials enrolling participants with amyloid-positive, early symptomatic Alzheimer's disease (AD) were analyzed for disease...
6.
Donanemab in Early Alzheimer's Disease
Mintun M, Lo A, Evans C, Wessels A, Ardayfio P, Andersen S, et al.
N Engl J Med . 2021 Mar; 384(18):1691-1704. PMID: 33720637
Background: A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment...
7.
Statistical properties of continuous composite scales and implications for drug development
Liu-Seifert H, Andersen S, Case M, Sparks J, Holdridge K, Wessels A, et al.
J Biopharm Stat . 2017 Apr; 27(6):1104-1114. PMID: 28402165
Little research has been conducted on the statistical properties of composite measures comprising linear combinations of continuous component scales. We assessed the quantitative relationship between the composites and their individual...
8.
Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment
Ball S, Ferguson M, Martinez J, Pangallo B, Nery E, Dellva M, et al.
J Clin Psychiatry . 2016 Apr; 77(5):635-42. PMID: 27035159
Objective: Three studies examined whether edivoxetine (a highly selective norepinephrine reuptake inhibitor) had efficacy as adjunctive therapy for patients with major depressive disorder (DSM-IV-TR) who were partial responders to selective...
9.
Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder
Martinez J, Ferguson M, Pangallo B, Oakes T, Sparks J, Dellva M, et al.
Drugs Context . 2015 May; 4:212279. PMID: 26005493
Objective: The aim of this analysis was to assess the safety profile of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor (SSRI) antidepressants. Methods: A pooled analysis was conducted...
10.
Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Ball S, Atkinson S, Sparks J, Bangs M, Goldberger C, Dube S
J Clin Psychopharmacol . 2015 Mar; 35(3):266-72. PMID: 25815754
Long-term safety, tolerability, and efficacy of adjunctive edivoxetine hydrochloride (hereafter edivoxetine), a highly selective and potent norepinephrine reuptake inhibitor, was assessed in patients with major depressive disorder (MDD) experiencing partial...